Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 96

1.

Polycythemia vera: new clinicopathologic perspectives.

Cao M, Olsen RJ, Zu Y.

Arch Pathol Lab Med. 2006 Aug;130(8):1126-32. Review.

PMID:
16879013
3.

Current diagnostic criteria for the chronic myeloproliferative disorders (MPD) essential thrombocythemia (ET), polycythemia vera (PV) and chronic idiopathic myelofibrosis (CIMF).

Michiels JJ, Bernema Z, Van Bockstaele D, De Raeve H, Schroyens W.

Pathol Biol (Paris). 2007 Mar;55(2):92-104. Epub 2006 Aug 21. Review.

PMID:
16919893
4.

Polycythemia vera: scientific advances and current practice.

Tefferi A, Spivak JL.

Semin Hematol. 2005 Oct;42(4):206-20. Review.

PMID:
16210034
5.

The 2001 World Health Organization and updated European clinical and pathological criteria for the diagnosis, classification, and staging of the Philadelphia chromosome-negative chronic myeloproliferative disorders.

Michiels JJ, De Raeve H, Berneman Z, Van Bockstaele D, Hebeda K, Lam K, Schroyens W.

Semin Thromb Hemost. 2006 Jun;32(4 Pt 2):307-40. Review.

PMID:
16810609
6.

Chronic idiopathic myelofibrosis: clinicopathologic features, pathogenesis, and prognosis.

Ahmed A, Chang CC.

Arch Pathol Lab Med. 2006 Aug;130(8):1133-43. Review.

PMID:
16879014
7.

The clinical phenotype of wild-type, heterozygous, and homozygous JAK2V617F in polycythemia vera.

Tefferi A, Lasho TL, Schwager SM, Strand JS, Elliott M, Mesa R, Li CY, Wadleigh M, Lee SJ, Gilliland DG.

Cancer. 2006 Feb 1;106(3):631-5.

9.

A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera.

James C, Ugo V, Le Couédic JP, Staerk J, Delhommeau F, Lacout C, Garçon L, Raslova H, Berger R, Bennaceur-Griscelli A, Villeval JL, Constantinescu SN, Casadevall N, Vainchenker W.

Nature. 2005 Apr 28;434(7037):1144-8.

PMID:
15793561
10.

JAK2V617F expression in murine hematopoietic cells leads to MPD mimicking human PV with secondary myelofibrosis.

Lacout C, Pisani DF, Tulliez M, Gachelin FM, Vainchenker W, Villeval JL.

Blood. 2006 Sep 1;108(5):1652-60. Epub 2006 May 2.

11.

Markers of myeloproliferative diseases in childhood polycythemia vera and essential thrombocythemia.

Teofili L, Giona F, Martini M, Cenci T, Guidi F, Torti L, Palumbo G, Amendola A, Foà R, Larocca LM.

J Clin Oncol. 2007 Mar 20;25(9):1048-53.

PMID:
17369568
12.

A gain-of-function mutation of JAK2 in myeloproliferative disorders.

Kralovics R, Passamonti F, Buser AS, Teo SS, Tiedt R, Passweg JR, Tichelli A, Cazzola M, Skoda RC.

N Engl J Med. 2005 Apr 28;352(17):1779-90.

13.

Altered gene expression in myeloproliferative disorders correlates with activation of signaling by the V617F mutation of Jak2.

Kralovics R, Teo SS, Buser AS, Brutsche M, Tiedt R, Tichelli A, Passamonti F, Pietra D, Cazzola M, Skoda RC.

Blood. 2005 Nov 15;106(10):3374-6. Epub 2005 Aug 4.

14.

Hematopoietic clonal dominance, stem cell mutations, and evolutionary pattern of JAK2V617F allele burden in polycythemia vera.

Angona A, Alvarez-Larrán A, Bellosillo B, Martínez-Avilés L, Camacho L, Fernández-Rodríguez C, Pairet S, Longarón R, Ancochea Á, Senín A, Florensa L, Besses C.

Eur J Haematol. 2015 Mar;94(3):251-7. doi: 10.1111/ejh.12425. Epub 2014 Sep 13.

PMID:
25082530
15.

Mutation screening for JAK2V617F: when to order the test and how to interpret the results.

Tefferi A, Pardanani A.

Leuk Res. 2006 Jun;30(6):739-44. Epub 2006 Feb 7.

PMID:
16460800
16.

Clinical and laboratory features, pathobiology of platelet-mediated thrombosis and bleeding complications, and the molecular etiology of essential thrombocythemia and polycythemia vera: therapeutic implications.

Michiels JJ, Berneman Z, Van Bockstaele D, van der Planken M, De Raeve H, Schroyens W.

Semin Thromb Hemost. 2006 Apr;32(3):174-207. Review.

PMID:
16673274
17.

An inhibitor of Janus kinase 2 prevents polycythemia in mice.

Mathur A, Mo JR, Kraus M, O'Hare E, Sinclair P, Young J, Zhao S, Wang Y, Kopinja J, Qu X, Reilly J, Walker D, Xu L, Aleksandrowicz D, Marshall G, Scott ML, Kohl NE, Bachman E.

Biochem Pharmacol. 2009 Aug 15;78(4):382-9. doi: 10.1016/j.bcp.2009.04.025. Epub 2009 May 3.

PMID:
19413997
18.

Diagnosis and therapy of polycythemia vera.

Lengfelder E, Merx K, Hehlmann R.

Semin Thromb Hemost. 2006 Apr;32(3):267-75. Review.

PMID:
16673281
19.

Prevalence of the activating JAK2 tyrosine kinase mutation V617F in the Budd-Chiari syndrome.

Patel RK, Lea NC, Heneghan MA, Westwood NB, Milojkovic D, Thanigaikumar M, Yallop D, Arya R, Pagliuca A, Gäken J, Wendon J, Heaton ND, Mufti GJ.

Gastroenterology. 2006 Jun;130(7):2031-8.

PMID:
16762626
20.

Increased death receptor resistance and FLIPshort expression in polycythemia vera erythroid precursor cells.

Zeuner A, Pedini F, Signore M, Ruscio G, Messina C, Tafuri A, Girelli G, Peschle C, De Maria R.

Blood. 2006 May 1;107(9):3495-502. Epub 2005 Dec 29.

Supplemental Content

Support Center